What is Stonewise?
Stonewise operates as an intelligent drug molecule research and development platform, leveraging cutting-edge artificial intelligence algorithms. By fusing computational chemistry knowledge, the company aims to empower new drug discovery from the molecular level. This innovative approach positions Stonewise at the forefront of pharmaceutical R&D, seeking to accelerate the identification and development of novel therapeutic compounds.
How much funding has Stonewise raised?
Stonewise has raised a total of $110M across 2 funding rounds:
Series A
$10M
Series B
$100M
Series A (2020): $10M with participation from Longhill Capital
Series B (2021): $100M led by Eastern Bell Capital, Legend Capital, Long Hill Capital, Lightspeed Venture Partners, Greater Bay Area Homeland Development Fund, and GL Ventures LLC
Key Investors in Stonewise
Legend Capital
Legend Capital is a prominent Chinese private equity fund manager with extensive experience in investing in innovation and growth enterprises. They manage significant capital and focus on companies with operations in or related to China, having a strong track record of investing in over 500 companies.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global venture capital firm that invests in early and growth-stage technology companies across various sectors, including enterprise software, consumer, fintech, and infrastructure. They partner with founders from seed stage through IPO or M&A.
Eastern Bell Capital
Eastern Bell Capital is an investor participating in Stonewise's funding round. Specific details on their investment focus are not provided, but their participation suggests alignment with the company's strategic goals in drug discovery.
What's next for Stonewise?
The recent major strategic investment signifies Stonewise's transition into a scaling phase, likely focused on expanding its research capabilities, advancing its drug pipeline, and potentially forging strategic partnerships. With significant backing, the company is poised to further develop its AI-driven drug discovery engine, aiming to bring novel molecules from the lab to clinical trials more efficiently. This capital infusion will be critical for navigating the complex and lengthy process of pharmaceutical development.
See full Stonewise company page
